Biologics

Bioventus launched its Osteomatrix+ bone graft for various spine and orthopedic applications.

Orthopedic fixation company Ossio received FDA 510(k) clearance for its Ossiofiber Bone Pin Family.

Marco Rodriguez, MD, founder of Baton Rouge, La.-based International Spine Institute, is using regenerative stem cell therapies as an alternative to spinal surgery.

Generex Biotechnology Corp. signed a letter to purchase Medisource Partners, an FDA-registered distributor.

SpinalCyte received a new Australian patent related to its fibroblast technology.

DiscGenics' injectable disc cell therapy, IDCT, passed the initial safety review of its first-in-human trial for moderate degenerative disc disease treatment.

JRF Ortho provides allograft joint repair solutions.

The FDA granted StemCyte permission to proceed with its phase 2 investigational new drug application for the Allogenic Human Leukocyte Antigen-Matched Umbilical Cord Blood Mononuclear Stem Cells (MC001).

Carmell Therapeutics, a developer of plasma-based bioactive materials to accelerate bone and soft tissue healing, welcomed Wendy DiCicco to its board of directors.

The Department of Defense granted a team of researchers at the University of Arizona in Tucson $2 million to study bone regrowth technology, according to The Brunswick News.